De novo synthesis increases exonuclease resistance in RNAi, suggesting improvements for gene silencing applications.
The 3′‐overhang of siRNAs is crucial for RISC assembly and stability, yet it is susceptible to nuclease degradation, significantly limiting its therapeutic applications. To address this challenge, we developed 3′‐C‐extended threose nucleic acid (TNA) analogs (ApioNA and BpioNA) using an asymmetric aldol synthesis strategy. Our results demonstrate that the BpioNA modification provides exceptional nuclease resistance, exhibiting a 60‐fold increase in half‐life compared to dT, while maintaining full gene silencing activity. Structural modeling revealed that these novel analogs preserve critical interactions with the Ago2 PAZ domain through adaptive binding geometries. This work not only addresses the stability‐activity trade‐off in siRNA design but also provides fundamental insights into the structure‐activity relationships (SARs) at the 3′‐terminus, paving the way for the development of durable RNAi therapeutics.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: